What question did this study set out to answer?

The study aims to evaluate the electrophysiologic effects and antiarrhythmic efficacy of sotalol in patients with ventricular tachyarrhythmias.

September 1, 1985CirculationOpen Access

Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias.

View Full Paper

Ask AI

Bookmark

Why the study?

Does sotalol improve electrophysiologic parameters and prevent arrhythmias in patients with refractory recurrent ventricular tachyarrhythmias?

Population

37 patients with refractory recurrent ventricular tachycardia/fibrillation (VT/VF)

Design

Cohort

Follow-up

mean 9.2 +/- 8.6 months

Authors

KNKoonlawee NademaneeElectrophysiology GFGregory FeldUniversity of California, San Diego JHJoAnn HendricksonUnited States Department of Veterans Affairs

Discussion

Member takes

Implication

May support sotalol in refractory VT/VF; hypothesis-generating and requires randomized trials before practice change.

Key Points

The study aims to evaluate the electrophysiologic effects and antiarrhythmic efficacy of sotalol in patients with ventricular tachyarrhythmias.
Assessed 37 patients with refractory recurrent ventricular tachycardia/fibrillation after intravenous and oral sotalol administration.
Evaluated the lengthening of effective refractory period and other electrocardiographic parameters.
Monitored PVC counts and arrhythmia recurrence over a mean follow-up period of 9.2 months.
Intravenous sotalol increased ERP significantly in atrium (+24.6%), AV node (+24.9%), and ventricle (+14.9%) with p < .01.
Sotalol reduced total PVC count by 73% (p < .01) and ventricular beats by 95% (p < .01).
45.5% of patients saw prevention of VT/VF reinduction, indicating long-term efficacy.

Structured PICO

Does sotalol improve electrophysiologic parameters and prevent arrhythmias in patients with refractory recurrent ventricular tachyarrhythmias?

Population

37 patients with refractory recurrent ventricular tachycardia/fibrillation (VT/VF)

Intervention

Sotalol administered intravenously (1.5 mg/kg) and orally (160 to 480 mg bid)

Outcome

Electrophysiologic effects (lengthening of effective refractory period), prevention of VT/VF reinduction, and reduction of premature ventricular complexes (PVCs) on Holter electrocardiogramsurrogate

Sotalol demonstrates significant electrophysiologic effects and efficacy in suppressing both inducible and spontaneous arrhythmias in patients with refractory life-threatening ventricular tachyarrhythmias.

Cite This Study

Nademanee et al. (1985) studied this question.

synapsesocial.com/papers/6a744a4dc64913a07da7fa07 https://doi.org/10.1161/01.cir.72.3.555

View Full Paper

Ask AI

Bookmark

Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias.

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias.

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider